Asthma Control in Severe Asthma Patients Treated with Tezepelumab: A Prospective, Observational, Real-World Evidence Study (ASCENT)
12 Years - n/a
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 May 2023 by AstraZeneca
No locations available
Participants with severe uncontrolled asthma will receive tezepelumab. Relevant demographics, baseline clinical data, and asthma control questionnaire-6 (ACQ-6) will be retrospectively collected. All patient reported outcomes (PROs) will be prospectively collected. Other outcomes of interest (tezepelumab patterns of utilization, lung function, asthma exacerbations, medication use, and healthcare resource utilization [HRU]) will be collected at baseline (retrospective collection for 52-week pre-index period during enrolment) and prospectively collected during enrolment for participants who enroll into the study before the first dose of tezepelumab, and for a period of up to 52 weeks (at Weeks 4, 12, 24, and 52) after the index date. The index date is defined as the date when participants receive the first dose of tezepelumab.